Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19

BACKGROUND: Many COVID-19 patients develop a hyperinflammatory response which activates blood coagulation and may contribute to the occurrence of thromboembolic complications. Blockade of interleukin-6, a key cytokine in COVID-19 pathogenesis, may improve the hypercoagulable state induced by inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Nisio, Marcello, Potere, Nicola, Candeloro, Matteo, Spacone, Antonella, Pieramati, Leonardo, Ferrandu, Giovanna, Rizzo, Giulia, La Vella, Matteo, Di Carlo, Silvio, Cibelli, Donatella, Parruti, Giustino, Levi, Marcel, Porreca, Ettore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608031/
https://www.ncbi.nlm.nih.gov/pubmed/33162299
http://dx.doi.org/10.1016/j.ejim.2020.10.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608031/
https://www.ncbi.nlm.nih.gov/pubmed/33162299
http://dx.doi.org/10.1016/j.ejim.2020.10.020

Ejemplares similares